CN105998755A - Mild-moxibustion medicine and mild-moxibustion apparatus for treating myopia and amblyopia - Google Patents
Mild-moxibustion medicine and mild-moxibustion apparatus for treating myopia and amblyopia Download PDFInfo
- Publication number
- CN105998755A CN105998755A CN201610584535.7A CN201610584535A CN105998755A CN 105998755 A CN105998755 A CN 105998755A CN 201610584535 A CN201610584535 A CN 201610584535A CN 105998755 A CN105998755 A CN 105998755A
- Authority
- CN
- China
- Prior art keywords
- moxa
- moxibustion
- amblyopia
- parts
- mild
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000009487 Amblyopia Diseases 0.000 title claims abstract description 101
- 208000001491 myopia Diseases 0.000 title claims abstract description 80
- 230000004379 myopia Effects 0.000 title claims abstract description 79
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 210000004279 orbit Anatomy 0.000 claims abstract description 65
- 210000001061 forehead Anatomy 0.000 claims abstract description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 16
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 14
- 241000628997 Flos Species 0.000 claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 14
- 235000008434 ginseng Nutrition 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 229920000742 Cotton Polymers 0.000 claims description 6
- 210000004534 cecum Anatomy 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 235000010894 Artemisia argyi Nutrition 0.000 claims description 4
- 244000030166 artemisia Species 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 11
- 230000000712 assembly Effects 0.000 abstract description 2
- 238000000429 assembly Methods 0.000 abstract description 2
- 244000245214 Mentha canadensis Species 0.000 abstract 1
- 235000001878 Mentha haplocalyx Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 230000004438 eyesight Effects 0.000 description 38
- 210000004185 liver Anatomy 0.000 description 15
- 240000005373 Panax quinquefolius Species 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 230000007547 defect Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 238000001467 acupuncture Methods 0.000 description 8
- 208000002173 dizziness Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 210000004709 eyebrow Anatomy 0.000 description 7
- 239000003517 fume Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 239000003546 flue gas Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010009185 Ciliary muscle spasm Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000009711 regulatory function Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 208000012886 Vertigo Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002485 combustion reaction Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000004402 high myopia Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009978 visual deterioration Effects 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 206010001912 Amblyopia strabismic Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000009406 ametropic amblyopia Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000004315 low visual acuity Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 201000009485 suppression amblyopia Diseases 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/06—Devices for heating or cooling such points within cell-life limits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a mild-moxibustion medicine and a mild-moxibustion apparatus for treating myopia and amblyopia. The mild-moxibustion medicine comprises, by weight, 20-30 parts of flos chrysanthemi, 4-8 parts of mentha haplocalyx, 10-16 parts of cornu saigae tataricae, 20-30 parts of radix rehmanniae, 12-20 parts of fructus lycii , 20-25 parts of rhizoma gastrodiae, 6-10 parts of radix ginseng, 6-10 parts of periostracum cicadae and 4-6 parts of borneolum syntheticum. The mild-moxibustion apparatus comprises an eyeshade body, a forehead mild-moxibustion frame and an eye socket assembly. One end of the eyeshade body is opened while the other end thereof is provided with an end cover. The forehead mild-moxibustion frame is arranged on the outer side of the eyeshade body, and a mild-moxibustion barrel unit is arranged in the forehead mild-moxibustion frame. The eye socket assembly is arranged on the inner side of the eyeshade body; mild-moxibustion barrel units or virtual-reality lens assemblies are arranged in the eye socket assembly, and a virtual-reality video player is arranged on the inner side of the end cover; and medicinal pads for treating myopia and amblyopia are arranged in the mild-moxibustion barrel units. The mild-moxibustion medicine and the mild-moxibustion apparatus have effective treatment effect for patients with myopia or amblyopia.
Description
Technical field
The present invention relates to treat the pharmaceutical composition technical field of ophthalmic, be specifically related to one and treat near-sighted weak
Depending on using Moxa medicine and thermotherapeutic apparatus.
Background technology
Amblyopia is that the common ophthalmology of people takes a disease.Amblyopia disease has the multiple origin cause of formation, such as, send out due to infant
Educate bad cause amblyopia, with eye mode bad cause amblyopia, the amblyopia caused due to heredity, due to
Old cause amblyopia, due to drug-induced amblyopia, the amblyopia that causes due to tobacco and wine excess etc..With
Time, universal due to electronic product in recent years, it brings while people's visual enjoyment also at major injury
The vision of people, make originally constantly to expand with regard to large number of myopia population, myopia amblyopia degree is continuous
Deepening, particularly virtual reality device, user needs directly to be worn on the head, and directly the eyes for user enter
Row closely plays video, it is provided that virtual 3D scene, makes user easily cause visual fatigue, easily occurs
Black eye and eye pouch, cause user the symptoms such as dizziness and nausea occur, and user can be caused in the course of time to occur regarding
Power declines and visual function damages, and ultimately results in user's amblyopia and myopia.
At present, China's amblyopia standard for correcting defects of vision≤0.8 or two eye vision poor >=2 row.Myopia amblyopia is one
Plant the oculopathy of serious harm child's visual function.If child myopia amblyopia eye is the most effectively controlled, easily develop
To high myopia, produce a series of pathologic and change, uncurable disease will be become after entering into person in middle and old age blind.According to
Statistics, the blind disease in old age more than 30% is to be stretched by high myopia posterior scleral and concurrent glaucoma, cataract
Caused by severe complication.If child strabismus amblyopia is treated the most in time, also may develop into
Low visual acuity or blind disease.
Therapeutic Method currently for amblyopia is mainly worn mirror treatment or uses amblyopia therapeutic equipment treatment, so
And above-mentioned Therapeutic Method can not help amblyopia patient to recover vision completely, often there is the phenomenon of recurrence,
This is primarily due to only mismatch the treatment carrying out other to infant wearing spectacles, and have ignored eyes
The training of visual performance.
Summary of the invention
For problems of the prior art, it is an object of the invention to provide one can be the most effective
Treatment myopia amblyopia Moxa medicine and preparation method thereof.
In order to achieve the above object, the present invention is achieved by the following technical solutions.
(1) one treats myopia amblyopia Moxa medicine, it is characterised in that include following weight portion
Chinese medicine component: Flos Chrysanthemi 20-30 part, Herba Menthae 4-8 part, Cornu Saigae Tataricae 10-16 part, Radix Rehmanniae 20-30 part, Fructus Lycii
12-20 part, Rhizoma Gastrodiae 20-25 part, Radix Ginseng 6-10 part, Periostracum Cicadae 6-10 part, Borneolum Syntheticum 4-6 part.
Preferably, the consumption of described Chinese medicine component is: Flos Chrysanthemi 30 parts, Herba Menthae 8 parts, Cornu Saigae Tataricae 16 parts, raw
30 parts of ground, Fructus Lycii 20 parts, 25 parts of Rhizoma Gastrodiae, Radix Ginseng 10 parts, Periostracum Cicadae 10 parts, Borneolum Syntheticum 6 parts.
(2) a kind of treat myopia amblyopia Moxa medicine preparation method, it is characterised in that include with
Lower step:
Step 1, by Flos Chrysanthemi, Herba Menthae, Cornu Saigae Tataricae, the Radix Rehmanniae, Fructus Lycii, Rhizoma Gastrodiae, Radix Ginseng, Periostracum Cicadae eight kinds
Chinese medicine component is smashed after drying to the material powder that fineness is 40 mesh；
Step 2, more described material powder is put in clear water, stir, soak 20 minutes, decoct 60 minutes；
Step 3, leaches medicinal residues, and adds Borneolum Syntheticum in filtrate, stir, must control after standing cooling
Treat the myopia amblyopia liquid preparation of Moxa medicine.
In above-mentioned Chinese medicine component,
Flos Chrysanthemi: sweet in the mouth, hardship, is slightly cold, and returns lung, Liver Channel, dispelling wind and heat pathogens, suppressing the hyperactive liver improving eyesight, heat-clearing and toxic substances removing,
For anemopyretic cold, dizziness of having a headache, conjunctival congestion and swelling pain, mesh is the most dim-sighted, sore and toxic.
Herba Menthae: acrid in the mouth is cool in nature, returns lung Liver Channel, dispelling wind and heat pathogens, the clear profit head, sore-throat relieving, and rash is soothing the liver
Circulation of qi promoting.For anemopyretic cold, pathogenic wind-warm is from the beginning of, headache, conjunctival congestion.
Cornu Saigae Tataricae: taste becomes, cold in nature, returns Liver Channel, heart channel, suppressing the hyperactive liver to relieve the wind syndrome, liver heat removing and eyesight improving, removing pathogenic heat from blood and toxic substance from the body,
Clearing away heat and relieving spasm, suppressing the hyperactive liver to relieve the wind syndrome, removing toxic substances and promoting subsidence of swelling, faint for coma convulsion, dizziness of having a headache, cataract.
The Radix Rehmanniae: sweet in the mouth, cold in nature.GUIXIN, liver, kidney channel, clearing away heat and cooling blood, YIN nourishing and the production of body fluid promoting.Enter for heat
Nutrient blood, maculae caused by violent heat pathogen, interior-heat is quenched one's thirst.
Fructus Lycii: bitter but slightly sweet taste, property are flat, return Liver and kidney warp, nourishing the liver and kidney, replenishing vital essence to improve eyesight.For dizziness
Tinnitus, interior-heat quenches one's thirst, blood deficiency and yellow complexion, and blurred vision is failed to understand.Modern pharmacological research shows: it has abundant dimension
Raw element and selenium, can promote amphiblestroid growth.
Rhizoma Gastrodiae: sweet in the mouth is pungent, property is flat, returns Liver Channel, endogenous wind stopping relieving convulsion, suppressing liver-YANG, dispelling wind and removing obstruction in the collateral.For
Headache dizziness, hands and feet caused by paralysis, numb limbs and tense tendons.
Radix Ginseng: sweet in the mouth, micro-hardship, warm in nature, return spleen, lung, the heart, kidney channel, strongly invigorating primordial QI, multiple arteries and veins takes off admittedly,
Invigorating the spleen to benefit the lung, promotes the production of body fluid and nourishes blood, Fructus Alpiniae Oxyphyllae of calming the nerves.For weak body and prostration, cold extremities faint pulse, insufficiency of the spleen lack of appetite, lung
Dyspnea due to deficiency is coughed, and Tianjin wound is thirsty, and interior-heat is quenched one's thirst.
Periostracum Cicadae: sweet in the mouth, cold in nature.Return lung, Liver Channel.Dispelling wind and heat pathogens, sore-throat relieving, rash, improving acuity of vision and removing nebula,
Can be used for cataract.Modern pharmacological research shows: it has enhancing retina nutrition and cellular activity, from
And alleviate electronic product blue light to amphiblestroid stimulation, reduce the damage to optic cell, safeguard normal
Visual performance.
Borneolum Syntheticum: acrid in the mouth, hardship, cool in nature, GUIXIN, spleen, lung meridian.Have one's ideas straightened out refreshment, clearing away heat to alleviate pain.For
Calentura coma, obstruction of qi in the chest and cardialgia, conjunctival congestion.All medicines can be led to enter between skin meridians.
It is a further object to provide one and treat myopia amblyopia medicated cushion and thermotherapeutic apparatus, permissible
It is worn on the head and the symptoms such as myopia, amblyopia astigmatism are effectively treated, it is also possible to make patient virtual in use
During real device, vision protected and improve.
(3) one treats myopia amblyopia medicated cushion, it is characterised in that described medicated cushion is in described treatment
The absorbent cotton of leaching system in the liquid preparation of myopia amblyopia Moxa medicine.
(4) one treats myopia amblyopia thermotherapeutic apparatus, it is characterised in that including:
Eyeshield body, described eyeshield body is box-like shell-like structure, and one end of described eyeshield body is opening
End, the other end is provided with end cap；Forehead Moxa frame, described forehead Moxa frame is arranged on described eyeshield body
Outside, be provided with described unit Moxa cylinder in described forehead Moxa frame；Eye frame assembly, described eye frame group
Part is arranged on the inner side of described eyeshield body, is provided with unit Moxa cylinder in described eye frame assembly, or described
Being provided with virtual reality Lens assembly in eye socket assembly, the inner side of described end cap is provided with virtual reality video
Playing device；Treatment myopia amblyopia medicated cushion it is provided with in described unit Moxa cylinder.
Treatment myopia amblyopia thermotherapeutic apparatus according to the present invention, opening of the eyeshield body of box-like shell-like structure
Mouth end, for covering on around the eye socket of patient, is provided with a unit in the forehead Moxa frame on eyeshield body
Moxa cylinder is for carrying out Moxa to the acupuncture point around the place between the eyebrows of patient, and eyeshield intrinsic eye socket assembly is respectively
The position of the eyes of corresponding patient is arranged, and the eye of patient can be carried out by the unit Moxa cylinder in eye socket assembly
Moxa.When the inner side of end cap can arrange virtual reality video play device, the unit in eye socket assembly
Moxa cylinder can be replaced virtual reality Lens assembly, and patient can use eyeshield body to fill as virtual reality
Putting use, now the unit Moxa cylinder in forehead Moxa frame can continue Moxa, is experiencing for reduction of patient
Spinning sensation during virtual reality, protects and improves the vision of patient.
As preferably, the sidewall of described eyeshield body is provided with first longitudinal chute, described eye socket group
Being provided with the first slide block on part, described first slide block is slidedly assemblied in described first longitudinal chute.
Treatment myopia amblyopia thermotherapeutic apparatus according to the present invention, first longitudinal chute is arranged on eyeshield body
Upper side wall on, the first slide block on eye socket assembly is slidedly assemblied in first longitudinal chute, makes the patient can
With longitudinally adjusted eye socket assembly, and then the distance of adjustment unit Moxa cylinder and eyes.
As preferably, described eye socket assembly includes vertically moving eye socket and transverse shifting eye socket, described vertical
Fixing to mobile eye socket and described first slide block and be connected, described transverse shifting eye socket is assemblied in described longitudinally shifting
In dynamic eye socket, in described transverse shifting eye socket, it is equipped with described unit Moxa cylinder or described virtual reality eyeglass
Assembly.
Treatment myopia amblyopia thermotherapeutic apparatus according to the present invention, in eye socket assembly vertically move eye socket with
First slide block is fixing to be connected, and transverse shifting eye socket is assemblied in and vertically moves in eye socket, and can vertically move
Sliding laterally in eye socket, transverse shifting eye socket is built-in is equipped with unit Moxa cylinder.When eyeshield body is as virtual
When real device uses, also can assemble virtual reality Lens assembly in transverse shifting eye socket, patient can be used to
Experiencing virtual real world.Wherein, can pass through between transverse shifting eye socket and single Moxa cylinder to be clasped,
Also by being separately positioned on the magnetic part secure fit of contact site, primarily serve location and prevent from departing from
Effect, facilitate dismounting and the installation of unit Moxa cylinder.
As preferably, described first slide block is provided with horizontal concrete chute, described transverse shifting eye socket sets
Being equipped with the second slide block, described second slide block is slidedly assemblied in described horizontal concrete chute.
Treatment myopia amblyopia thermotherapeutic apparatus according to the present invention, the first slide block is provided with and leads to inside it
Horizontal concrete chute, the second slide block device on transverse shifting eye socket in horizontal concrete chute, by regulation second
Slide block position in horizontal concrete chute, the just position of scalable transverse shifting eye socket, can make controlling of the present invention
Treat the patient that myopia amblyopia thermotherapeutic apparatus adapts to have different interpupillary distance.
As preferably, described first slide block stretches out described eyeshield body by described first longitudinal chute
Outside, described second slide block stretches out the outside of described eyeshield body by described horizontal concrete chute.
Treatment myopia amblyopia thermotherapeutic apparatus according to the present invention, the first slide block is stretched by first longitudinal chute
Go out the outside of eyeshield body, make patient need not unload and take apart eyeshield body and just can regulate unit Moxa at any time
Cylinder and the distance of eyes, the second slide block stretches out the outside of eyeshield body by the horizontal concrete chute on the first slide block,
Make different patient that unit Moxa cylinder can be directed at the eyes of oneself.
As preferably, the middle part of the upper edge of the sidewall of described eyeshield body is provided with second longitudinal chute,
Described forehead Moxa frame is assemblied in described second longitudinal chute.
Treatment myopia amblyopia thermotherapeutic apparatus according to the present invention, forehead Moxa frame is assemblied in eyeshield body
In second longitudinal chute at the middle part of the upper edge of sidewall, can make patient's adjustment unit Moxa cylinder at any time and its
The distance at place between the eyebrows position, improves the comfort of product, moreover it is possible to prevent from being burned.
As preferably, described unit Moxa cylinder includes that moxibustion cylinder and cartridge case, one end of described moxibustion cylinder are opening
End, the other end is provided with mesh plate, and described mesh plate is towards the opening direction of described eyeshield body, described
One end of cartridge case is opening, and the other end is cecum, and the inner side of the cecum of described cartridge case is provided with medicine torr,
Being fixed with Chinese mugwort pin in described medicine torr, the opening of described moxibustion cylinder is fastened and connected with the opening of described cartridge case,
It is both provided with venthole on the sidewall of described moxibustion cylinder and described cartridge case.
Treatment myopia amblyopia thermotherapeutic apparatus according to the present invention, the barrel of moxibustion cylinder is provided with heat-insulation layer,
Heat-insulation layer can prevent the high temperature failure transverse shifting eye socket in cartridge case or forehead Moxa frame.It is fixed on Ai Zhenhe
After moxa roll in medicine torr and medicine are ignited, its treatment flue gas will flow out from mesh plate, carry out human body
Moxa medical treatment, owing to cartridge case and moxibustion cylinder fasten, the flue gas that moxibustion cylinder is identical with the venthole on cartridge case, unnecessary
To flow out from venthole.
The treatment myopia amblyopia Moxa medicine of the present invention uses above-mentioned thermotherapeutic apparatus that patient carries out smoked moxibustion treatment
Treating, patient smokes moxibustion every day 1 time, the most smoked moxibustion 20 minutes.
Smoked moxibustion is divided into moxibustion and smoked two parts.Motherland's medical science is thought: blood stored in the liver, has one's ideas straightened out in mesh, and mesh obtains blood
And can regard.If impairment of blood by looking for a long time, loss of nutrient of eyes and fall ill.Smoked moxibustion therapy treatment myopia, amblyopia are to nourish liver
Kidney, QI invigorating improving eyesight, dredging the meridian is principle.
Moxibustion is moxa-moxibustion, says acupuncture point reality moxibustion, " Elementary Medicine " with moxa roll: medicine too late, pin institute less than,
Must moxibustion it.In the present invention, moxa roll used is made with 8: 1: 1 with 5 years Chen Ai, Folium Mori, Stigma Crocis.Take
Eye acupuncture point with the space between the eyebrows, Clear and Bright, praise bamboo, yang white, think of bamboo sky, Sibai, Yuyao, boy Liao, chengqi
It is main, joins moxibustion shu-back point.Wherein Yintang acupoint is named again temmoku cave, the 3rd eye that namely it has often been said,
There is the effect of improving eyesight stuffy nose relieving, mind tranquilizing and the heart calming.
Smoked is stifling, utilizes the Chinese medicine in moxa roll combustion heating medicated cushion so that it is effective ingredient volatilizees, stifling
Skin enters internal microcirculqtory system, simultaneously meridians dredging, QI and blood regulating, activating cell tissue, excited
Optic cell, elimination eyes muscular fatigue, ciliary spasm, the regulatory function of recovery dioptric tissue, thus soon
Fast, safe, firm raising vision, greatly strengthen the effect of moxa-moxibustion.
Compared with prior art, the invention have the benefit that
The present invention according to the theory of the traditional Chinese medical science " monarch ", use Flos Chrysanthemi, Herba Menthae, Cornu Saigae Tataricae, the Radix Rehmanniae,
Fructus Lycii, Rhizoma Gastrodiae, Radix Ginseng, Periostracum Cicadae and Borneolum Syntheticum multiple Chinese herbal medicine compatibility in proportion, makes and can treat myopia
The amblyopia liquid preparation of Moxa medicine, and absorbent cotton is immersed in aforesaid liquid preparation and makes medicated cushion, will
Medicated cushion is put in the treatment myopia amblyopia thermotherapeutic apparatus of the present invention, use the mode of smoked moxibustion for myopia,
The treatment of amblyopia patient, meridians dredging, QI and blood regulating, activating cell tissue, excited optic cell, disappear
Except eyes muscular fatigue, ciliary spasm, recover the regulatory function of dioptric tissue, thus quickly, safety, surely
Solid raising vision.
Accompanying drawing explanation
With specific embodiment, the present invention is described in further details below in conjunction with the accompanying drawings.
Fig. 1 is the overall structure simplified schematic diagram of the treatment myopia amblyopia thermotherapeutic apparatus that the present invention proposes；
Fig. 2 is the cross section structure schematic diagram in Fig. 1 at A；
Fig. 3 is the overall structure schematic diagram of the described unit Moxa cylinder in the present invention；
Fig. 4 is the decomposition texture schematic diagram of the unit Moxa cylinder in Fig. 3.
In Fig. 1 to Fig. 4: 1 eyeshield body；101 first longitudinal chutes；102 second longitudinal chutes；2
End cap；3 forehead Moxa frames；4 unit Moxa cylinders；401 ventholes；410 moxibustion cylinders；411 mesh plates；
420 cartridge cases；421 medicine torr；422 acupuncture needles；5 eye socket assemblies；510 vertically move eye socket；511
One slide block；512 horizontal concrete chutes；513 guide rods；520 transverse shifting eye sockets；521 second slide blocks；6 is soft
Pad.
Detailed description of the invention
Of the present invention treatment myopia amblyopia Moxa is expanded on further below in conjunction with specific embodiment
Medicine and beneficial effect thereof.
Embodiment 1
The present invention provides one to treat myopia amblyopia Moxa medicine, is first according to following quality and is equipped with Chinese medicine
Component: Flos Chrysanthemi 30g, Herba Menthae 8g, Cornu Saigae Tataricae 16g, Radix Rehmanniae 30g, Fructus Lycii 20g, Rhizoma Gastrodiae 25g, Radix Ginseng
10g, Periostracum Cicadae 10g, Borneolum Syntheticum 6g；Then by Flos Chrysanthemi, Herba Menthae, Cornu Saigae Tataricae, the Radix Rehmanniae, Fructus Lycii, Rhizoma Gastrodiae,
Radix Ginseng, eight kinds of Chinese medicine components of Periostracum Cicadae are smashed after drying to the material powder that fineness is 40 mesh；Again material powder is put into Sheng
In having the marmite of 1500mL clear water, stir, soak 20 minutes, after big fire is heated to boiling, be adjusted to
Little fire decocts 60 minutes；Leach medicinal residues after cooling, and in filtrate, add Borneolum Syntheticum, stir, to obtain final product
The treatment myopia amblyopia liquid preparation of Moxa medicine.
Embodiment 2
The present invention provides one to treat myopia amblyopia Moxa medicine, is first according to following quality and is equipped with Chinese medicine
Component: Flos Chrysanthemi 25g, Herba Menthae 6g, Cornu Saigae Tataricae 13g, Radix Rehmanniae 25g, Fructus Lycii 16g, Rhizoma Gastrodiae 23g, Radix Ginseng
8g, Periostracum Cicadae 8g, Borneolum Syntheticum 5g；Then by Flos Chrysanthemi, Herba Menthae, Cornu Saigae Tataricae, the Radix Rehmanniae, Fructus Lycii, Rhizoma Gastrodiae,
Radix Ginseng, eight kinds of Chinese medicine components of Periostracum Cicadae are smashed after drying to the material powder that fineness is 40 mesh；Again material powder is put into Sheng
In having the marmite of 1500mL clear water, stir, soak 20 minutes, after big fire is heated to boiling, be adjusted to
Little fire decocts 60 minutes；Leach medicinal residues after cooling, and in filtrate, add Borneolum Syntheticum, stir, to obtain final product
The treatment myopia amblyopia liquid preparation of Moxa medicine.
Embodiment 3
Use the treatment myopia amblyopia Moxa drugs on patients obtained by above-described embodiment to treat, make
As follows by method: cotton of first getting it filled is immersed in liquid preparation prepared by above-described embodiment makes medicated cushion, and
Medicated cushion is put in thermotherapeutic apparatus, thus realizes the effective treatment to patient.
With reference to Fig. 1 and Fig. 2, the present invention proposes one and treats myopia amblyopia thermotherapeutic apparatus, including: eyeshield
Body 1, described eyeshield body 1 is box-like shell-like structure, and one end of described eyeshield body 1 is opening,
The other end is provided with end cap 2；Forehead Moxa frame, described forehead Moxa frame is arranged on described eyeshield body 1
Outside, is provided with described unit Moxa cylinder in described forehead Moxa frame；Eye frame assembly, described eye frame assembly
It is arranged on the inner side of described eyeshield body 1, in described eye frame assembly, is provided with unit Moxa cylinder, or described
Being provided with virtual reality (VR) Lens assembly in eye socket assembly 5, the inner side of described end cap 2 is provided with void
Intend reality (VR) video play device；Treatment myopia amblyopia medication it is provided with in described unit Moxa cylinder 4
Pad.
The opening of the eyeshield body 1 of box-like shell-like structure is for covering on around the eye socket of patient, and eyeshield is originally
A unit Moxa cylinder 4 it is provided with around the place between the eyebrows to patient in forehead Moxa frame 3 on body 1
Acupuncture point carries out Moxa, and the position of the eyes of the most corresponding patient of the eye socket assembly 5 in eyeshield body 1 is arranged,
Unit Moxa cylinder 4 in eye socket assembly 5 can carry out Moxa to the eye of patient.When the inner side of end cap 2 can
During to arrange virtual reality video play device, the unit Moxa cylinder 4 in eye socket assembly 5 can be replaced void
Intend real lens assembly, patient can use eyeshield body 1 to use as virtual reality device, now before
Unit Moxa cylinder 4 in volume Moxa frame 3 can continue Moxa, for reduction of patient when experiencing virtual reality
Spinning sensation, improve patient vision.
It is provided with first longitudinal chute 101 on the sidewall of described eyeshield body 1, described eye socket assembly 5 sets
Being equipped with the first slide block 511, described first slide block 511 is slidedly assemblied in described first longitudinal chute 101.
First longitudinal chute 101 is arranged on the upper side wall of eyeshield body 1, first on eye socket assembly 5
Slide block 511 is slidedly assemblied in first longitudinal chute 101, make patient can with longitudinally adjusted eye socket assembly 5,
And then the distance of adjustment unit Moxa cylinder 4 and eyes.
Described eye socket assembly 5 includes vertically moving eye socket 510 and transverse shifting eye socket 520, described longitudinally shifting
Dynamic eye socket 510 is fixing with described first slide block 511 to be connected, and described transverse shifting eye socket 520 is assemblied in institute
State and vertically move in eye socket 510, in described transverse shifting eye socket 520, be equipped with described unit Moxa cylinder 4
Or described virtual reality Lens assembly.
Eye socket assembly 5 vertically moves that eye socket 510 is fixing with the first slide block 511 to be connected, vertically moves
Being provided with guide hole on eye socket 510, the inner side of eyeshield body 1 is provided with guide rod 513, guide rod 513 and guide hole
Matching, make to vertically move eye socket 510 more stable in sliding process, transverse shifting eye socket 520 fills
Fit over and vertically move in eye socket 510, and can slide laterally in vertically moving eye socket 510, transverse shifting
Eye socket 520 is built-in is equipped with unit Moxa cylinder 4.When eyeshield body 1 uses as virtual reality device, horizontal
Also can assemble virtual reality Lens assembly in mobile eye socket 520, patient can be used to experiencing virtual reality generation
Boundary.Wherein, can also may be used by being clasped between transverse shifting eye socket 520 and single Moxa cylinder 410
By being separately positioned on the magnetic part secure fit of contact site, primarily serve location and prevent the work departed from
With, facilitate dismounting and the installation of unit Moxa cylinder 4.
It is provided with horizontal concrete chute 512 on described first slide block 511, described transverse shifting eye socket 520 is arranged
The second slide block 521, described second slide block 521 is had to be slidedly assemblied in described horizontal concrete chute 512.
The horizontal concrete chute 512 led to inside it it is provided with, on transverse shifting eye socket 520 on first slide block 511
The second slide block 521 device in horizontal concrete chute 512, by regulating the second slide block 521 at horizontal concrete chute
Position in 512, the just position of scalable transverse shifting eye socket 520, the treatment myopia that can make the present invention is weak
Depending on adapting to the patient with different interpupillary distance with thermotherapeutic apparatus.
Described first slide block 511 is stretched out outside described eyeshield body 1 by described first longitudinal chute 101
Side, described second slide block 521 stretches out the outside of described eyeshield body 1 by described horizontal concrete chute 512.
First slide block 511 stretches out the outside of eyeshield body 1 by first longitudinal chute 101, makes patient not
With unloading and take apart eyeshield body 1 and just can regulate at any time the distance of unit Moxa cylinder 4 and eyes, second is sliding
Block 521 stretches out the outside of eyeshield body 1 by the horizontal concrete chute 512 on the first slide block 511, makes difference
Unit Moxa cylinder 4 can be directed at the eyes of oneself by patient.
The middle part of the upper edge of the sidewall of described eyeshield body 1 is provided with second longitudinal chute 102, described before
Volume Moxa frame is assemblied in described second longitudinal chute 102.
Forehead Moxa frame 3 is assemblied in second longitudinal chute at the middle part of the upper edge of the sidewall of eyeshield body 1
In 102, patient's adjustment unit Moxa cylinder 4 at any time and the distance at its place between the eyebrows position can be made, improve making of product
By comfort level, moreover it is possible to prevent from being burned.
The left and right sides of described eyeshield body 1 is respectively arranged with bandage hole, two described sides with holes respectively with
The two ends of one elastic cord connect.
The two ends of elastic cord are with holes with the side of the left and right sides of eyeshield body 1 respectively to be connected, and patient may utilize
Eyeshield body 1 is worn on the head by elastic cord.
The edge of the opening of described eyeshield body 1 is provided with bar shaped cushion 6.
Bar shaped cushion 6 liner, at the edge of the opening of eyeshield body 1, has sealing function, main
Be improve user of service face and eyeshield body 1 between the comfort contacted.
With reference to Fig. 3 and Fig. 4, described unit Moxa cylinder includes moxibustion cylinder and cartridge case 420, one end of described moxibustion cylinder
For opening, the other end is provided with mesh plate 411, and described mesh plate 411 is towards described eyeshield body 1
Opening direction, one end of described cartridge case 420 is opening, and the other end is cecum, described cartridge case 420
The inner side of cecum is provided with medicine torr 421, and described medicine torr 421 is fixed with Chinese mugwort pin 422, described moxibustion cylinder 410
The opening of opening and described cartridge case 420 be fastened and connected, described moxibustion cylinder 410 and described cartridge case 420
Sidewall on be both provided with venthole 401.
Being provided with heat-insulation layer on the barrel of moxibustion cylinder 410, heat-insulation layer can prevent the high temperature failure in cartridge case 420
Transverse shifting eye socket 520520 or forehead Moxa frame 3.It is fixed on the moxa roll in Chinese mugwort pin and medicine torr and medicine quilt
After lighting, its treatment flue gas will flow out from mesh plate 411, human body carry out Moxa medical treatment, due to medicine
Cylinder 420 and moxibustion cylinder 410 fasten, and moxibustion cylinder 410 is identical with the venthole 401 on cartridge case 420, unnecessary
Flue gas will flow out from venthole 401.
It is provided with smoke-dispelling hole on the sidewall of described eyeshield body 1 and/or end cap 2.
Smoke-dispelling hole on the sidewall of eyeshield body 1 and/or end cap 2 is used for making from moxibustion cylinder 410 and cartridge case 420
On venthole 401 in flow out flue gas can be dissipated to outside eyeshield body 1.
Embodiment 4
The treatment myopia amblyopia Moxa drugs on patients using above-described embodiment gained treats, by medicine
Cotton is put in the treatment myopia amblyopia Moxa medicine of above-described embodiment gained, after soaking 120 minutes, takes out,
Must be used for treating the medicated cushion of myopia amblyopia, medicated cushion be put in the unit Moxa cylinder of thermotherapeutic apparatus, use temperature
Moxibustion device carries out Moxa to the eyes of the acupuncture point around the place between the eyebrows of patient and patient, and patient is carried out every day 1
Secondary, the fume and moxibustion therapeutic of each 20 minutes.
Accept out-patient 223 example totally 411 amblyopia eye patients, the maleest 93 examples, female 130 example, Huan Zhejun for medical treatment
For the age the child in 3-12 year.The amblyopia degree of patient is divided into slightly, moderate and severe, wherein, gently
Degree is the 0.8-0.6 that corrects defects of vision, and moderate is the 0.5-0.2 that corrects defects of vision, and severe equals to or less than for correcting defects of vision
0.1；Through the treatment myopia amblyopia of the present invention with after Moxa Drug therapy, the evaluation criteria of healing is for correcting
Vision reaches more than 0.8.
Therapeutic outcome is as follows:
For the fume and moxibustion therapeutic of patients with mild, cure rate is 96.15%, for the fume and moxibustion therapeutic of moderate patient,
Cure rate is 63.29%, and total cure rate reaches 66.67%.And for patients with mild, treatment duration was at 45 days
Within, wherein, the patient of 27% was cured in 15 days, and the patient of 62% was cured in 30 days, corrected
Vision restoration is to more than 0.8；For moderate patient, treatment duration is within 100 days, wherein, and the trouble of 60%
Person was cured within 60 days；For severe patient, treatment duration is longer, substantially need to be more than 100 days.
It addition, for amblyopia treatment curative effect of different nature be: for ametropic amblyopia, cure rate
Being 76.47%, for anisometropic amblyopia, cure rate is 38.09%, for strabismic amblyopia, cures
Rate is 33.33%.
It can be seen from the results above that use the treatment myopia amblyopia Moxa medicine of the present invention to use smoked moxibustion
Therapeutic Method patient is treated, utilize the treatment myopia amblyopia temperature in moxa roll combustion heating medicated cushion
Moxibustion medicine so that it is effective ingredient volatilizees, stifling skin enters internal, microcirculqtory system, dredges through logical simultaneously
Network, QI and blood regulating, activating cell tissue, excited optic cell, eliminate eyes muscular fatigue, ciliary spasm,
Recover dioptric tissue regulatory function, thus quickly, safe, consolidate raising vision, hence it is evident that reach to control
Treat the effect of amblyopia.
Embodiment 5
The treatment myopia amblyopia Moxa medicine using above-described embodiment gained combines VR training to be carried out patient
Treatment, puts into absorbent cotton in the treatment myopia amblyopia Moxa medicine of above-described embodiment gained, soaks 120 points
Zhong Hou, takes out, and must be used for treating the medicated cushion of myopia amblyopia, medicated cushion is put into the unit Moxa of thermotherapeutic apparatus
In Tong, use thermotherapeutic apparatus that the acupuncture point around the place between the eyebrows of patient carries out smoked moxibustion, patient carried out every day 1 time,
The fume and moxibustion therapeutic of each 20 minutes, coordinates VR training during smoked moxibustion.
Accept out-patient 223 example totally 411 amblyopia eye patients, the maleest 93 examples, female 130 example, Huan Zhejun for medical treatment
For the age the child in 3-12 year.The amblyopia degree of patient is divided into slightly, moderate and severe, wherein, gently
Degree is the 0.8-0.6 that corrects defects of vision, and moderate is the 0.5-0.2 that corrects defects of vision, and severe equals to or less than for correcting defects of vision
0.1；The evaluation criteria cured reaches more than 0.8 for correcting defects of vision, and occurs without dizziness not when experiencing VR
Suitable sensation.
Therapeutic outcome for different amblyopia degree compares, and result is as shown in table 1:
Table 1
Patient is treated by employing fume and moxibustion therapeutic the Therapeutic Method coordinating VR to train, for different amblyopias
The comparison curing duration of degree, result is as described in Table 2.
Table 2
Patient is treated, for heterogeneity by employing fume and moxibustion therapeutic the Therapeutic Method coordinating VR to train
Amblyopia treating effect as shown in table 3.
Table 3
It can be seen from the results above that by the treatment myopia amblyopia of the present invention Moxa medicine and VR training knot
Closing and treat patient, moxa-moxibustion stimulates eye acupuncture point, dredging the meridian, and centering is calmed the nerves, and strengthening cell has
Oxygen metabolism, blood circulation promoting, increase the regulatory function of part tissue of eye, produce during to eliminate viewing VR
Dizziness and the damage to vision, promote vision.And the energy of Ai Zhu burning urges treatment myopia in medicated cushion
The amblyopia volatilization of Moxa effective ingredient, enters internal microcirculation, enhances the effect of moxa-moxibustion, phase
Ratio, in patient only carries out the better of fume and moxibustion therapeutic, shortens simultaneously and treats the course for the treatment of, improve healing
Rate.
Embodiment 6
Patient 1, Lee * *, man, 12 years old, and people from Fuping wears mirror 4 years, joins mirror treatment in Xi'an hospital,
Optometry: right eye+225 ° × 50 ° × 36 °, left eye+200 ° × 75 ° × 120 °；Naked vision: right
Eye 0.4, left eye 0.4；Correct defects of vision: right eye 0.6, left eye 0.8, use by the treatment myopia amblyopia of the present invention
Moxa medicinal fuming moxibustion also coordinates VR to train, and surveys: right eye 1.2, left eye 1.2, recover to face after two months.
Patient 2, a * *, man, 12 years old, and people from Pucheng wears mirror 4 years, optometry: right eye-325 ° × 50 ° ×
120 °, left eye-300 ° × 75 ° × 30 °；Naked vision: right eye 0.3, left eye 0.25；Correct defects of vision:
Right eye 0.8, left eye 0.8, with the treatment myopia amblyopia Moxa medicinal fuming moxibustion of the present invention and coordinate VR to train,
Survey after 2 months: the naked vision right side 1.2, left 1.2.
Patient 3, and shut out * *, and man, 12 years old, people from Fuping, right eye 0.6, left eye 0.5, with the treatment of the present invention
Myopia amblyopia Moxa medicinal fuming moxibustion also coordinates VR to train, and within 15 days, surveys, right eye 1.5, left eye 1.2.
After 3 months, above-mentioned patient is carried out Effect of follow-up visit by telephone, without obvious visual deterioration phenomenon produce, 6 months with
Visit, produce without obvious visual deterioration phenomenon.
Embodiment 7
In multiple community, Fuping County, randomly select the amblyopia patient of 300 example all ages and classes, it is made
With the treatment myopia amblyopia Moxa medicinal fuming moxibustion of the present invention and coordinate the treatment that VR trains, result shows:
Produce vertigo symptoms has 6 people, accounts for the 2% of sum, does seance myopia amblyopia Moxa medicinal fuming moxibustion
And coordinate VR to train, what vision promoted has 212 people, accounts for the 70.67% of sum, does three treatment myopia
Amblyopia Moxa medicinal fuming moxibustion also coordinates VR to train, and what vision promoted has 288 people, accounts for the 96% of sum.
As seen from the above embodiment, the treatment myopia amblyopia of the present invention with Moxa medicine according to the traditional Chinese medical science " the monarch and his subjects
Assistant make " theory, use Flos Chrysanthemi, Herba Menthae, Cornu Saigae Tataricae, the Radix Rehmanniae, Fructus Lycii, Rhizoma Gastrodiae, Radix Ginseng, Cicadae
Slough off pure Chinese herbal medicine in proportion compatibility multiple with Borneolum Syntheticum, make the medicine that can be used for treating myopia amblyopia, and will
It uses the mode of smoked moxibustion for the treatment to myopia amblyopia patient, meridians dredging, QI and blood regulating, activation
Cell tissue, excited optic cell, eliminate eyes muscular fatigue, ciliary spasm, recover the tune of dioptric tissue
Joint function, thus quickly, safe, firm raising vision.Used smoked moxibustion and coordinate VR to train
Myopia amblyopia patient is treated by Therapeutic Method, can not only eliminate damage, fall to vision when watching VR
The symptom that low dizziness is uncomfortable, and lifting vision that can be quick, effective, lasting.Myopia amblyopia is controlled
Treat, practical, safe and efficient, shorten treatment time, improve curative effect.The especially myopia to child
Amblyopia treatment, evident in efficacy, patient can be made to eliminate symptom, recover vision.
Although, the present invention has been made by this specification the most with a general description of the specific embodiments detailed
Description, but on the basis of the present invention, it can be made some modifications or improvements, this is to art technology
It is apparent from for personnel.Therefore, these done without departing from theon the basis of the spirit of the present invention are repaiied
Change or improve, belonging to the scope of protection of present invention.
Claims (10)
1. a treatment myopia amblyopia Moxa medicine, it is characterised in that include the Chinese medicine of following weight portion
Component: Flos Chrysanthemi 20-30 part, Herba Menthae 4-8 part, Cornu Saigae Tataricae 10-16 part, Radix Rehmanniae 20-30 part, Fructus Lycii
12-20 part, Rhizoma Gastrodiae 20-25 part, Radix Ginseng 6-10 part, Periostracum Cicadae 6-10 part, Borneolum Syntheticum 4-6 part.
Treatment myopia amblyopia Moxa medicine the most according to claim 1, it is characterised in that described
The consumption of Chinese medicine component is: Flos Chrysanthemi 30 parts, Herba Menthae 8 parts, Cornu Saigae Tataricae 16 parts, 30 parts of the Radix Rehmanniae, Fructus Lycii 20
Part, 25 parts of Rhizoma Gastrodiae, Radix Ginseng 10 parts, Periostracum Cicadae 10 parts, Borneolum Syntheticum 6 parts.
3. the preparation method treating myopia amblyopia Moxa medicine, it is characterised in that include following step
Rapid:
Step 1, by Flos Chrysanthemi, Herba Menthae, Cornu Saigae Tataricae, the Radix Rehmanniae, Fructus Lycii, Rhizoma Gastrodiae, Radix Ginseng, Periostracum Cicadae eight kinds
Chinese medicine component cleans, smashes to the material powder that fineness is 40 mesh after drying；
Step 2, more described material powder is put in clear water, stir, soak 20-30 minute, decoct 60-80
Minute；
Step 3, leaches medicinal residues, and adds Borneolum Syntheticum in filtrate, stir, must control after standing cooling
Treat the myopia amblyopia liquid preparation of Moxa medicine.
4. a treatment myopia amblyopia medicated cushion, it is characterised in that described medicated cushion is in claim 3 institute
The absorbent cotton of leaching system in the liquid preparation of the treatment myopia amblyopia Moxa medicine stated.
5. a treatment myopia amblyopia thermotherapeutic apparatus, it is characterised in that including:
Eyeshield body (1), described eyeshield body (1) is box-like shell-like structure, described eyeshield body (1)
One end be opening, the other end is provided with end cap (2)；
Forehead Moxa frame (3), described forehead Moxa frame (3) is arranged on outside described eyeshield body (1)
Side, is provided with described unit Moxa cylinder (4) in described forehead Moxa frame (3)；
Eye frame assembly (5), described eye frame assembly (5) is arranged on the inner side of described eyeshield body (1),
Unit Moxa cylinder (4) it is provided with in described eye frame assembly (5), or
Virtual reality Lens assembly, the inner side of described end cap (2) it is provided with in described eye socket assembly (5)
It is provided with virtual reality video play device；
Treatment myopia amblyopia medicated cushion it is provided with in described unit Moxa cylinder (4).
Treatment myopia amblyopia thermotherapeutic apparatus the most according to claim 5, it is characterised in that described
First longitudinal chute (101) it is provided with, on described eye socket assembly (5) on the sidewall of eyeshield body (1)
Being provided with the first slide block (511), described first slide block (511) is slidedly assemblied in described first longitudinal chute
(101) in.
Treatment myopia amblyopia thermotherapeutic apparatus the most according to claim 6, it is characterised in that described
Eye socket assembly (5) includes vertically moving frame (510) and transverse shifting frame (520), described in vertically move
Frame (510) is fixing with described first slide block (511) to be connected, and described transverse shifting frame (520) is assemblied in
Described vertically move frame (510) in, be equipped with described unit Moxa in described transverse shifting frame (520)
Cylinder (4) or described virtual reality Lens assembly.
Treatment myopia amblyopia thermotherapeutic apparatus the most according to claim 7, it is characterised in that described
Being provided with horizontal concrete chute (512) on first slide block (511), described transverse shifting frame (520) is upper to be arranged
The second slide block (521), described second slide block (521) is had to be slidedly assemblied in described horizontal concrete chute (512)
In.
Treatment myopia amblyopia thermotherapeutic apparatus the most according to claim 5, it is characterised in that described
The middle part of the upper edge of the sidewall of eyeshield body (1) is provided with second longitudinal chute (102), described forehead
Moxa frame (3) is assemblied in described second longitudinal chute (102).
Treatment myopia amblyopia thermotherapeutic apparatus the most according to claim 5, it is characterised in that institute
State unit Moxa cylinder (4) and include moxibustion cylinder (410) and cartridge case (420), one end of described moxibustion cylinder (410)
For opening, the other end is provided with mesh plate (411), and one end of described mesh plate (411) is towards described
The opening direction of eyeshield body (1), one end of described cartridge case (420) is opening, and the other end is blind
End, the inner side of the cecum of described cartridge case (420) is provided with medicated cushion (421), on described medicated cushion (421)
It is fixed with Chinese mugwort pin (422), the opening of described moxibustion cylinder (410) and the opening of described cartridge case (420)
It is fastened and connected, the sidewall of described moxibustion cylinder (410) and described cartridge case (420) is both provided with venthole (401).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610584535.7A CN105998755A (en) | 2016-07-22 | 2016-07-22 | Mild-moxibustion medicine and mild-moxibustion apparatus for treating myopia and amblyopia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610584535.7A CN105998755A (en) | 2016-07-22 | 2016-07-22 | Mild-moxibustion medicine and mild-moxibustion apparatus for treating myopia and amblyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105998755A true CN105998755A (en) | 2016-10-12 |
Family
ID=57116338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610584535.7A Pending CN105998755A (en) | 2016-07-22 | 2016-07-22 | Mild-moxibustion medicine and mild-moxibustion apparatus for treating myopia and amblyopia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105998755A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109316343A (en) * | 2018-10-25 | 2019-02-12 | 粟光 | A new type of eye moxibustion device |
| CN113262162A (en) * | 2021-06-30 | 2021-08-17 | 湖北蕲艾堂科技有限公司 | Permanent eye moxibustion tool |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331974A (en) * | 2000-12-25 | 2002-01-23 | 徐万富 | Eyesight improving medicine liquid |
| CN1853588A (en) * | 2005-04-28 | 2006-11-01 | 宁夏锐目视力保健研究中心（有限公司） | Six-parallel vision comprehensive health-care technology |
-
2016
- 2016-07-22 CN CN201610584535.7A patent/CN105998755A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1331974A (en) * | 2000-12-25 | 2002-01-23 | 徐万富 | Eyesight improving medicine liquid |
| CN1853588A (en) * | 2005-04-28 | 2006-11-01 | 宁夏锐目视力保健研究中心（有限公司） | Six-parallel vision comprehensive health-care technology |
Non-Patent Citations (1)
| Title |
|---|
| 张智银: "穴位贴压治疗儿童弱视44例", 《河南中医》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109316343A (en) * | 2018-10-25 | 2019-02-12 | 粟光 | A new type of eye moxibustion device |
| CN113262162A (en) * | 2021-06-30 | 2021-08-17 | 湖北蕲艾堂科技有限公司 | Permanent eye moxibustion tool |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102139038A (en) | Chinese herbal preparation for treating eye diseases | |
| CN101822872A (en) | Eye near-infrared light therapeutic apparatus | |
| CN106901896A (en) | A kind of detoxifying health-care eyeshade | |
| CN111035748A (en) | Traditional Chinese medicine composition for improving myopia, external application preparation for improving myopia and eye patch for improving myopia | |
| CN201019908Y (en) | Ophthalmology treating instrument | |
| CN105998755A (en) | Mild-moxibustion medicine and mild-moxibustion apparatus for treating myopia and amblyopia | |
| CN106491962A (en) | A kind of pharmaceutical composition and thermotherapy eyesight improving eye patch and eyeshade for eye thermotherapy | |
| CN106491987A (en) | A kind of treat traditional Chinese medicine fumigating steaming liquid of cataract and preparation method thereof | |
| CN103446408A (en) | Traditional Chinese medicine for treating myopia | |
| CN105708936A (en) | Traditional Chinese medicinal composition for treating myopia, amblyopia and asthenopia | |
| CN107050226A (en) | A kind of Chinese herb medicine eye for treating eye visual fatigue disease applies combination paste and preparation method | |
| CN110433232A (en) | A kind of compound huang lian granules of external application and preparation method thereof | |
| CN106214875A (en) | For improving the medicine for external use of juvenile myopia, its preparation method and application thereof | |
| CN103340992A (en) | Eye ointment for adjusting eyesight | |
| CN203458528U (en) | Eye treatment device | |
| CN206026670U (en) | Ice platform magnetism fire appearance | |
| CN113181238A (en) | Injection for acupoint injection therapy for treating myopia | |
| CN109700928A (en) | A kind of pack and its massage application method of promotion vision restoration | |
| CN110302357A (en) | A kind of external application eyesight-improving health care function Chinese medicine composition and preparation method thereof | |
| CN104523981A (en) | Traditional Chinese medicine preparation for treating optic neuritis and preparation method | |
| CN106344729A (en) | External medicine for treating near-sightedness of adult, and preparation method and application of external medicine | |
| CN104706852A (en) | External traditional Chinese medicine composition capable of improving eyesight, preparation method and applications thereof | |
| CN1062164C (en) | Oral medicine pill for curing myopia and amblyopia | |
| CN103520412A (en) | Chinese medicinal decoction for treating meniere vertigo | |
| CN102579724B (en) | Chinese medicine composition for treating glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |